Treatment of pediatric IgA nephropathy

Keith K. Lau, Lavjay Butani

Research output: Contribution to journalArticle

Abstract

IgA nephropathy is the most common chronic glomerulopathy in children and young adults. Although most of the early studies on pediatric IgA nephropathy concluded that it was a benign condition, more recent data have shown that a significant proportion of children progress to end-stage renal disease. It is now obvious that IgA nephropathy in children is not as benign as previously thought. Physicians who care for children with IgA nephropathy should be aware of this risk of progression to renal insufficiency and make treatment a priority. Strict attention should be given to modify any coexisting morbidities that may further predispose young patients to renal deterioration. The pharmacologic agents and therapeutic options used to manage this common disease are reviewed, and a recommended approach is presented.

Original languageEnglish (US)
Pages (from-to)70-76
Number of pages7
JournalHong Kong Journal of Nephrology
Volume9
Issue number2
DOIs
StatePublished - 2007

Fingerprint

Immunoglobulin A
Pediatrics
Therapeutics
Child Care
Chronic Kidney Failure
Renal Insufficiency
Young Adult
Morbidity
Physicians
Kidney

Keywords

  • Chronic glomerulopathy
  • End-stage renal disease
  • Pediatric IgA nephropathy

ASJC Scopus subject areas

  • Nephrology

Cite this

Treatment of pediatric IgA nephropathy. / Lau, Keith K.; Butani, Lavjay.

In: Hong Kong Journal of Nephrology, Vol. 9, No. 2, 2007, p. 70-76.

Research output: Contribution to journalArticle

@article{1247015d886a42d492183fa9ecc05ebb,
title = "Treatment of pediatric IgA nephropathy",
abstract = "IgA nephropathy is the most common chronic glomerulopathy in children and young adults. Although most of the early studies on pediatric IgA nephropathy concluded that it was a benign condition, more recent data have shown that a significant proportion of children progress to end-stage renal disease. It is now obvious that IgA nephropathy in children is not as benign as previously thought. Physicians who care for children with IgA nephropathy should be aware of this risk of progression to renal insufficiency and make treatment a priority. Strict attention should be given to modify any coexisting morbidities that may further predispose young patients to renal deterioration. The pharmacologic agents and therapeutic options used to manage this common disease are reviewed, and a recommended approach is presented.",
keywords = "Chronic glomerulopathy, End-stage renal disease, Pediatric IgA nephropathy",
author = "Lau, {Keith K.} and Lavjay Butani",
year = "2007",
doi = "10.1016/S1561-5413(08)60003-4",
language = "English (US)",
volume = "9",
pages = "70--76",
journal = "Hong Kong Journal of Nephrology",
issn = "1561-5413",
publisher = "Elsevier (Singapore) Pte Ltd",
number = "2",

}

TY - JOUR

T1 - Treatment of pediatric IgA nephropathy

AU - Lau, Keith K.

AU - Butani, Lavjay

PY - 2007

Y1 - 2007

N2 - IgA nephropathy is the most common chronic glomerulopathy in children and young adults. Although most of the early studies on pediatric IgA nephropathy concluded that it was a benign condition, more recent data have shown that a significant proportion of children progress to end-stage renal disease. It is now obvious that IgA nephropathy in children is not as benign as previously thought. Physicians who care for children with IgA nephropathy should be aware of this risk of progression to renal insufficiency and make treatment a priority. Strict attention should be given to modify any coexisting morbidities that may further predispose young patients to renal deterioration. The pharmacologic agents and therapeutic options used to manage this common disease are reviewed, and a recommended approach is presented.

AB - IgA nephropathy is the most common chronic glomerulopathy in children and young adults. Although most of the early studies on pediatric IgA nephropathy concluded that it was a benign condition, more recent data have shown that a significant proportion of children progress to end-stage renal disease. It is now obvious that IgA nephropathy in children is not as benign as previously thought. Physicians who care for children with IgA nephropathy should be aware of this risk of progression to renal insufficiency and make treatment a priority. Strict attention should be given to modify any coexisting morbidities that may further predispose young patients to renal deterioration. The pharmacologic agents and therapeutic options used to manage this common disease are reviewed, and a recommended approach is presented.

KW - Chronic glomerulopathy

KW - End-stage renal disease

KW - Pediatric IgA nephropathy

UR - http://www.scopus.com/inward/record.url?scp=36749079887&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36749079887&partnerID=8YFLogxK

U2 - 10.1016/S1561-5413(08)60003-4

DO - 10.1016/S1561-5413(08)60003-4

M3 - Article

AN - SCOPUS:36749079887

VL - 9

SP - 70

EP - 76

JO - Hong Kong Journal of Nephrology

JF - Hong Kong Journal of Nephrology

SN - 1561-5413

IS - 2

ER -